BFM
MBX

Boothbay Fund Management’s MBX Biosciences MBX Stock Holding History

Boothbay Fund Management’s Portfolio MBX Stock Details MBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-72,800
Closed -$1.27M – 2456
2025
Q3 		$1.27M Buy
+72,800
New +$973K 0.02% 734

Other funds holding MBX

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $176M AUM 208.78% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Boothbay Fund Management's MBX Position: Q1 2026 in Review

Boothbay Fund Management opened a new position in MBX Biosciences (MBX) in Q1 2026: 208,049 shares worth $6.21M. The stake represents 0.08% of the portfolio and ranks #258 among its holdings. This is a return to the name: Boothbay Fund Management previously reported a position in MBX as recently as Q3 2025.

Boothbay Fund Management first reported a position in MBX in Q3 2025 and has held it in 2 quarters since. 157 funds tracked by Wall St. Rank hold MBX as of Q1 2026.

  • Boothbay Fund Management held 208,049 shares of MBX Biosciences worth $6.21M as of Q1 2026.
  • MBX Biosciences was a new Boothbay Fund Management position in Q1 2026.
  • MBX Biosciences made up 0.08% of Boothbay Fund Management's portfolio in Q1 2026, its #258 holding.
  • Boothbay Fund Management first reported a position in MBX Biosciences in Q3 2025 and has held it in 2 quarters since.
  • 157 funds tracked by Wall St. Rank held MBX Biosciences as of Q1 2026.

Based on Boothbay Fund Management's 13F filing for Q1 2026, filed 15 May 2026.